3B)

3B). == The percent of methylated reference (PMR) values for SEPT9 above a PMR threshold of 1% were detected in 4.2% (1/24) of NED, 100% (26/26) of adenoma and 97.1% (33/34) of CRC tissues. PMR differences between NED vs. adenoma and NED vs. CRC comparisons were significant (p<0.001). In matching plasma samples using a PMR cut-off level of 0.01%, SEPT9 methylation was 8.3% (2/24) of NED, 30.8% (8/26) of adenoma and 88.2% (30/34) of CRC. Significant PMR differences were observed between NED vs. CRC (p<0.01) and adenoma vs. CRC (p<0.01). Significant differences (p<0.01) were found in the amount of cfDNA (circulating cell-free DNA) between NED and CRC, and a modest correlation was observed between mSEPT9 NF-ATC concentration and cfDNA of cancer (R2= 0.48). The level of Septin-9 protein in tissues was inversely correlated to mSEPT9 levels with abundant expression in normals, and diminished expression in adenomas and tumors. == Conclusions == Methylated SEPT9 was detected in all tissue samples. In plasma samples, elevated mSEPT9 values were detected in CRC, but not in adenomas. Tissue levels of mSEPT9 alone are not sufficient to predict mSEPT9 levels in plasma. Additional parameters including the amount of cfDNA in plasma appear to also play a role. == Introduction == Colorectal cancer (CRC) is the most frequently diagnosed malignant tumor after lung cancer with an incidence of 13.1% in Europe[1]. Screening of CRC is highly cost effective; the cost per life-year saved compares favorably with other preventive treatments, such as therapy of moderate hypertension[2]. The 1-year and 5-year survivals of CRC are 83.2% and 64.3%, respectively[3]. Most long-term survivors of CRC are patients in whom the tumor was diagnosed early, as SAR191801 this offers effective therapeutic inventions for reducing CRC mortality. Early diagnostics should be focused on adenomas since most CRCs evolve on the basis of these premalignant lesions[4]. CRC screening tests currently in use can be divided into two groups: 1) non-invasive tests for primary cancer detection, such as guaiac fecal occult blood test (gFOBT), fecal immunochemical test (FIT) and stool DNA tests; 2) invasive tests that can detect cancer and advanced lesions, such as flexible sigmoidoscopy, colonoscopy, double-contrast barium enema and virtual colonoscopy[5]. However, all of these tests have limitations. Patients’ compliance to the noninvasive screening methods is high, but at the cost of relatively lower sensitivity and specificity. CRC-associated mortality can only be reduced by 1525% using gFOBT, and it detects only 3375% of CRC[6]. Expensive high quality human hemoglobin-specific FIT detects CRC with a sensitivity of about 6085%[7]. Furthermore it has a lower prevalence of positives (6.3%) than FOBT (10.3%)[8]. Denters et al. found that 87% of advanced adenomas (larger than 1 cm) can be detected with gFOBT and 75% with FIT. They found that the detection of proximal advanced adenomas is better with FIT compared to gFOBT (27% vs. 17%)[9]. Eighty-five percent of cancerous colonic lesions and 53% of adenomas (size 1 cm) can be detected by using stool DNA test (marker panel: methylated vimentin, NDRG4, BMP3, TFPI2 and the mutation marker K-ras). The test has 89% specificity for both lesions[10]. The disadvantage of this test is that it has only a poor acceptance in the general population. Although invasive colonoscopy has the highest sensitivity and specificity for CRC and adenoma detection, it has the lowest patient compliance rate due to the need of bowel preparation. Additional limitations of this method are the required expertise, as well as higher costs, invasiveness, availability and occasionally adverse events resulting from the procedure. Since the currently established methods for CRC screening either suffer from insufficient effectiveness or from low patient compliance, better and more patient-friendly methods could improve the early diagnosis of CRC. Blood-based screening techniques offer a new diagnostic tool for benign and malignant colorectal lesions. Wang et al.[11]detected SAR191801 the presence of APC, K-ras and p53 mutations in serum from patients SAR191801 with CRC. They found that these genes may be potential molecular markers for poor clinical outcome of CRC. Methylated Septin 9 (mSEPT9) was found to be a valuable marker for CRC[12][14]. Septin proteins are a group of GTP-binding proteins and belong to a superclass of P-loop GTPases. Septin genes were originally detected in yeast as a critical gene in cell division[15]. They have important role in several cellular processes, such as providing rigidity to the cell membrane, serving as scaffolds to recruit proteins to specific subcellular locales, creating membrane diffusion barriers to establish discrete cellular domains and they play a role in cell polarity determination[15],[16]. The molecular mechanism of Septin 9 (SEPT9) in colon tumorigenesis is still largely unknown; the gene has 18 distinct transcripts generated by alternative splicing and encodes 15 polypeptides and has not been thoroughly studied[17]. This complexity may explain the apparent SAR191801 role of SEPT9 in.